I don’t think that there is any effective, proven way to predict medication response. I have been involved in research on biomarkers—we call them “response endophenotypes”—such as EEG, where we look at the physiologic response of the brain to a new drug and try to determine whether the drug will work for that patient.
Read More
Psychiatrists have long wondered whether someday we might have an objective way to diagnose depression, in much the same way an internist orders a blood test or X-ray. A recent article suggests that just such a test might be on the horizon. Is it the real deal?
Read More
A heated debate over how well psychiatric medications actually work has led some authorities in our field to suggest that psychiatry is currently experiencing a “crisis of confidence.”
Read More
In 2011 in the pages of TCPR, we asked, “What’s new in antidepressant treatment?” The answer was “not much” (TCPR, April 2011). In 2012, unfortunately, the answer isn’t very different.
Read More
Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.jpg?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
